Drug and vaccine safety

WHO / A. Zaidi / WHO / M. Nieuwenhof / WHO / A. Jallanzo
A health worker gives free medicine to patients in district headquarters hospital (DHQ) Kasur. At the Cholera treatment center in Beira. Guinea: Ebola outbreak response

Overview

Patient safety is fundamental to delivering quality essential health services.

Research to improve detection, assessment, and prevention of the adverse effects of medicines and vaccines, as well as research to strengthen pharmacovigilance systems for safe and effective introduction of new health technologies such as new TB treatments will ultimately contribute to enhancing patient care and patient safety.

TDR’s contribution to improving patient safety

ShORRT initiative

In the latest World Health Organization (WHO) guidelines on drug-resistant tuberculosis (DR-TB) treatment, modifications to the recommended all-oral treatments for multidrug- ...

Active TB drug safety monitoring and management (aDSM)

Active tuberculosis (TB) drug safety monitoring and management (aDSM) is a key component for the use of new and repurposed TB drugs.

Innovative approaches for improving drug & vaccine safety

Webinars on South-South sharing of experiences on innovative approaches for improving drug and vaccine safety

Central registry for epidemiological surveillance of drug safety in pregnancy

A broad collaboration is underway between the World Health Organization (including TDR) and external partners to assess the consequences to mothers and their newly born children of ...

Related news

16 March 2022

News release

Strengthening tuberculosis drug safety monitoring and management in Indonesia

21 June 2021

News release

Strengthening COVID-19 vaccine safety monitoring in African countries

23 March 2021

News release

Understanding and addressing barriers to TB safety monitoring in Africa

8 December 2020

News release

The ShORRT operational research initiative a year on: spotlight on Nigeria

Other activities

Partnerships